DNA damage response pathways and cell cycle checkpoints in colorectal cancer: Current concepts and future perspectives for targeted treatment

Current Cancer Drug Targets

Volumn 12, Issue 4, 2012, Pages 356-371

  Solier, S ^a   Zhang, Y W ^a   Ballestrero, A ^b   Pommier, Y ^a   Zoppoli, G ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Cell cycle; Chk2; Colorectal cancer; DNA damage response; Irinotecan; Oxaliplatin

Indexed keywords

AG 14361; BENZIMIDAZOLE; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CAMPTOSTAR; CAMPTOTHECIN; CEP 9722; DNA DIRECTED DNA POLYMERASE BETA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FIRTECAN; FIRTECAN GLUCURONIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GPI 15427; INIPARIB; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; OXALIPLATIN; SSAR 240550; STAT3 PROTEIN; TEMOZOLOMIDE; THYMIDYLATE SYNTHASE; TRIFLURIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER SURVIVAL; CELL CYCLE CHECKPOINT; COLORECTAL CANCER; DIARRHEA; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG EFFICACY; DRUG POTENTIATION; GENETIC TRANSCRIPTION; HUMAN; INTESTINE INJURY; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PROTEIN INTERACTION; RADIOSENSITIZATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; COLORECTAL NEOPLASMS; DNA DAMAGE; DNA REPAIR; FEMALE; HUMANS; MALE; MICE; MOLECULAR TARGETED THERAPY; POLY(ADP-RIBOSE) POLYMERASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84860298408     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912800190901     Document Type: Review

References (199)

1. Joyce, G. F. The antiquity of RNA-based evolution. Nature 2002, 418 (6894), 214-221.
2. Shechner, D. M.; Grant, R. A.; Bagby, S. C.; Koldobskaya, Y.; Piccirilli, J. A.; Bartel, D. P. Crystal structure of the catalytic core of an RNA-polymerase ribozyme. Science 2009, 326 (5957), 1271-1275.
3. Jackson, S. P.; Bartek, J. The DNA-damage response in human biology and disease. Nature 2009, 461 (7267), 1071-1078.
4. Kastan, M. B.; Bartek, J. Cell-cycle checkpoints and cancer. Nature 2004, 432 (7015), 316-323.
5. Stracker, T. H.; Usui, T.; Petrini, J. H. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst). 2009, 8 (9), 1047-1054.
6. Conti, C.; Seiler, J. A.; Pommier, Y. The mammalian DNA replication elongation checkpoint: implication of Chk1 and relationship with origin firing as determined by single DNA molecule and single cell analyses. Cell Cycle 2007, 6 (22), 2760-2767.
7. Pommier, Y.; Sordet, O.; Rao, V. A.; Zhang, H.; Kohn, K. W. Targeting chk2 kinase: molecular interaction maps and therapeutic rationale. Curr. Pharm. Des. 2005, 11 (22), 2855-2872.
8. Vogelstein, B.; Kinzler, K. W. Cancer genes and the pathways they control. Nat. Med. 2004, 10 (8), 789-799.
9. Michor, F.; Iwasa, Y.; Vogelstein, B.; Lengauer, C.; Nowak, M. A., Can chromosomal instability initiate tumorigenesis? Semin. Cancer Biol. 2005, 15 (1), 43-49.
10. Li, G. M. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008, 18 (1), 85-98.
11. Jiricny, J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell. Biol. 2006, 7 (5), 335-346.
12. Cummings, O. W. Pathology of the adenoma-carcinoma sequence: from aberrant crypt focus to invasive carcinoma. Semin. Gastrointest. Dis. 2000, 11 (4), 229-237.
13. Cardoso, J.; Molenaar, L.; de Menezes, R. X.; van Leerdam, M.; Rosenberg, C.; Moslein, G.; Sampson, J.; Morreau, H.; Boer, J. M.; Fodde, R. Chromosomal instability in MYH- and APC- mutant adenomatous polyps. Cancer Res. 2006, 66 (5), 2514-2519.
14. Hadjihannas, M. V.; Behrens, J. CIN By WNT: growth pathways, mitotic control and chromosomal instability in cancer. Cell Cycle 2006, 5 (18), 2077-2081.
15. Popat, S.; Hubner, R.; Houlston, R. S. Systematic review of micro satellite instability and colorectal cancer prognosis. J. Clin. Oncol. 2005, 23 (3), 609-618.
16. Loeb, L. A. A mutator phenotype in cancer. Cancer Res. 2001, 61 (8), 3230-3239.
17. Longley, D. B.; Harkin, D. P.; Johnston, P. G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3 (5) 330-338
18. Sampath, D.; Rao, V. A.; Plunkett, W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003, 22 (56), 9063-9074.
19. Wyatt, M. D.; Wilson, D. M., Participation of DNA repair in the response to 5-fluorouracil. Cell Mol. Life Sci. 2009, 66 (5), 788-799.
20. Segditsas, S.; Tomlinson, I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006, 25 (57), 7531-7537.
21. Parker, A. R.; Sieber, O. M.; Shi, C.; Hua, L.; Takao, M.; Tomlinson, I. P.; Eshleman, J. R. Cells with pathogenic mutations in the human MUTYH gene are defective in DNA damage binding and repair. Carcinogenesis 2005, 26 (11), 2010-2018.
22. Al-Tassan, N.; Chmiel, N. H.; Maynard, J.; Fleming, N.; Livingston, A. L.; Williams, G. T.; Hodges, A. K.; Davies, D. R.; David, S. S.; Sampson, J. R.; Cheadle, J. P. Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors. Nat. Genet. 2002, 30 (2), 227-232.
23. Sieber, O. M.; Lipton, L.; Crabtree, M.; Heinimann, K.; Fidalgo, P.; Phillips, R. K.; Bisgaard, M. L.; Orntoft, T. F.; Aaltonen, L. A.; Hodgson, S. V.; Thomas, H. J.; Tomlinson, I. P. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N. Engl. J. Med. 2003, 348 (9), 791-799.
24. Venkatachalam, R.; Ligtenberg, M. J.; Hoogerbrugge, N.; de Bruijn, D. R.; Kuiper, R. P.; Geurts van Kessel, A. The epigenetics of (hereditary) colorectal cancer. Cancer Genet. Cytogenet. 2010, 203 (1), 1-6.
25. Jasperson, K. W.; Tuohy, T. M.; Neklason, D. W.; Burt, R. W. Hereditary and familial colon cancer. Gastroenterology 2010, 138 (6), 2044-2058.
26. Lammi, L.; Arte, S.; Somer, M.; Jarvinen, H.; Lahermo, P.; Thesleff, I.; Pirinen, S.; Nieminen, P. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet. 2004, 74 (5), 1043-1050.
27. Kilpivaara, O.; Alhopuro, P.; Vahteristo, P.; Aaltonen, L. A.; Nevanlinna, H. CHEK2 I157T associates with familial and sporadic colorectal cancer. J. Med. Genet. 2006, 43 (7), e34.
28. Reinhardt, H. C.; Yaffe, M. B. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr. Opin. Cell Biol. 2009, 21 (2), 245-255.
29. Jeghers, H.; Mc, K. V.; Katz, K. H. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance. N. Engl. J. Med. 1949, 241 (26), 1031-1036.
30. Farmer, R. G.; Hawk, W. A.; Turnbull, R. B., Jr. The spectrum of the Peutz-Jeghers syndrome. report of 3 cases. Am. J. Dig. Dis. 1963, 8, 953-961.
31. Hemminki, A.; Tomlinson, I.; Markie, D.; Jarvinen, H.; Sistonen, P.; Bjorkqvist, A. M.; Knuutila, S.; Salovaara, R.; Bodmer, W.; Shibata, D.; de la Chapelle, A.; Aaltonen, L. A. Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat. Genet. 1997, 15 (1), 87-90.
32. Jenne, D. E.; Reimann, H.; Nezu, J.; Friedel, W.; Loff, S.; Jeschke, R.; Muller, O.; Back, W.; Zimmer, M. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 1998, 18 (1), 38-43.
33. Hemminki, A.; Markie, D.; Tomlinson, I.; Avizienyte, E.; Roth, S.; Loukola, A.; Bignell, G.; Warren, W.; Aminoff, M.; Hoglund, P.; Jarvinen, H.; Kristo, P.; Pelin, K.; Ridanpaa, M.; Salovaara, R.; Toro, T.; Bodmer, W.; Olschwang, S.; Olsen, A. S.; Stratton, M. R.; de la Chapelle, A.; Aaltonen, L. A. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998, 391 (6663), 184-187.
34. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6 (10), 789-802.
35. Wall, M. E.; Wani, M. C.; Taylor, H. Isolation and chemicalcharacterization of antitumor agents from plants. Cancer Treat. Rep. 976, 60 (8), 1011-1030.
36. Saltz, L. B.; Cox, J. V.; Blanke, C.; Rosen, L. S.; Fehrenbacher, L.; Moore, M. J.; Maroun, J. A.; Ackland, S. P.; Locker, P. K.; Pirotta, N.; Elfring, G. L.; Miller, L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal Cancer Irinotecan StudyGroup. N. Engl. J. Med. 2000, 343 (13), 905-914.
37. Douillard, J. Y.; Cunningham, D.; Roth, A. D.; Navarro, M.; James, R. D.; Karasek, P.; Jandik, P.; Iveson, T.; Carmichael, J.; Alakl, M.; Gruia, G.; Awad, L.; Rougier, P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentrerandomised trial. Lancet 2000, 355 (9209), 1041-1047.
38. Xu, Y.; Villalona-Calero, M. A. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann. Oncol. 2002, 13 (12), 1841-1851.
39. Song, Y.; Shao, Z.; Dexheimer, T. S.; Scher, E. S.; Pommier, Y.; Cushman, M. Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors. J. Med. Chem. 2010, 53 (5), 1979-1989.
40. Wu, M. H.; Yan, B.; Humerickhouse, R.; Dolan, M. E. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin. Cancer Res. 2002, 8 (8), 2696-2700.
41. Charasson, V.; Bellott, R.; Meynard, D.; Longy, M.; Gorry, P.; Robert, J. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin. Pharmacol. Ther. 2004, 76 (6), 528-535.
42. Morton, C. L.; Wadkins, R. M.; Danks, M. K.; Potter, P. M. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res. 1999, 59 (7), 1458-1463.
43. Boige, V.; Mendiboure, J.; Pignon, J. P.; Loriot, M. A.; Castaing, M.; Barrois, M.; Malka, D.; Tregouet, D. A.; Bouche, O.; Le Corre, D.; Miran, I.; Mulot, C.; Ducreux, M.; Beaune, P.; Laurent-Puig, P. Pharma cogenetic assessment of toxicity and outcome in patientswith metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J. Clin. Oncol. 2010, 28 (15), 2556-2564.
44. McLeod, H. L.; Sargent, D. J.; Marsh, S.; Green, E. M.; King, C. R.; Fuchs, C. S.; Ramanathan, R. K.; Williamson, S. K.; Findlay, B. P.; Thibodeau, S. N.; Grothey, A.; Morton, R. F.; Goldberg, R. M. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J. Clin. Oncol. 2010, 28 (20), 3227-3233.
45. Freyer, G.; Duret, A.; Milano, G.; Chatelut, E.; Rebischung, C.; Delord, J. P.; Merrouche, Y.; Lledo, G.; Etienne, M. C.; Falandry, C. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. Anticancer Res. 2011, 31 (1), 359-366.
46. Jinno, H.; Saeki, M.; Saito, Y.; Tanaka-Kagawa, T.; Hanioka, N.; Sai, K.; Kaniwa, N.; Ando, M.; Shirao, K.; Minami, H.; Ohtsu, A.; Yoshida, T.; Saijo, N.; Ozawa, S.; Sawada, J. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J. Pharmacol. Exp. Ther. 2003, 306 (2), 688-693.
47. Monaghan, G.; Ryan, M.; Seddon, R.; Hume, R.; Burchell, B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996, 347 (9001), 578-581.
48. Chu, X. Y.; Suzuki, H.; Ueda, K.; Kato, Y.; Akiyama, S.; Sugiyama, Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J. Pharmacol. Exp. Ther. 1999, 288 (2), 735-741.
49. Mathijssen, R. H.; Marsh, S.; Karlsson, M. O.; Xie, R.; Baker, S. D.; Verweij, J.; Sparreboom, A.; McLeod, H. L. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res. 2003, 9 (9), 3246-3253.
50. Pillot, G. A.; Read, W. L.; Hennenfent, K. L.; Marsh, S.; Gao, F.; Viswanathan, A.; Cummings, K.; McLeod, H. L.; Govindan, R. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J. Thorac Oncol. 2006, 1 (9), 972-978.
51. Ulrich, C. M.; Robien, K.; McLeod, H. L. Cancer pharma cogenetics: polymorphisms, pathways and beyond. Nat. Rev. Cancer 2003, 3 (12), 912-920.
52. O'Dwyer, P. J.; Catalano, R. B. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J. Clin. Oncol. 2006, 24 (28), 4534-4538.
53. Cha, P. C.; Mushiroda, T.; Zembutsu, H.; Harada, H.; Shinoda, N.; Kawamoto, S.; Shimoyama, R.; Nishidate, T.; Furuhata, T.; Sasaki, K.; Hirata, K.; Nakamura, Y. Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J. Hum. Genet. 2009, 54 (10), 572-580.
54. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 2006, 6 (10), 813-823.
55. Kiselev, E.; Dexheimer, T. S.; Pommier, Y.; Cushman, M. Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines topoisomerase I inhibitors and potential anticancer agents. J. Med.Chem. 2010, 53 (24), 8716-8726.
56. Pfister, T. D.; Reinhold, W. C.; Agama, K.; Gupta, S.; Khin, S. A.; Kinders, R. J.; Parchment, R. E.; Tomaszewski, J. E.; Doroshow, J. H.; Pommier, Y. Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol. Cancer Ther. 2009, 8 (7), 1878-1884.
57. Das, B. B.; Dexheimer, T. S.; Maddali, K.; Pommier, Y. Role of tyrosyl-DNA phosphodiesterase (TDP1) in mitochondria. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (46), 19790-19795.
58. Dexheimer, T. S.; Antony, S.; Marchand, C.; Pommier, Y. Tyrosyl- DNA phosphodiesterase as a target for anticancer therapy. Anticancer Agents Med. Chem. 2008, 8 (4), 381-389.
59. Zhang, Y. W.; Regairaz, M.; Seiler, J. A.; Agama, K. K.; Doroshow, J. H.; Pommier, Y. Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res. 2011, 39 (9), 3607-3620.
60. Kidani, Y.; Noji, M.; Tashiro, T. Anti tumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers. Gann. 1980, 71(5), 637-643.
61. Rixe, O.; Ortuzar, W.; Alvarez, M.; Parker, R.; Reed, E.; Paull, K.; Fojo, T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol. 1996, 52 (12), 1855-1865.
62. Mathe, G.; Kidani, Y.; Segiguchi, M.; Eriguchi, M.; Fredj, G.; Peytavin, G.; Misset, J. L.; Brienza, S.; de Vassals, F.; Chenu, E. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother. 1989, 43 (4), 237-250.
63. Di Francesco, A. M.; Ruggiero, A.; Riccardi, R., Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol. Life Sci. 2002, 59 (11), 1914-1927.
64. de Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; Cassidy, J.; Boni, C.; Cortes-Funes, H.; Cervantes, A.; Freyer, G.; Papamichael, D.; Le Bail, N.; Louvet, C.; Hendler, D.; de Braud, F.; Wilson, C.; Morvan, F.; Bonetti, A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal Cancer J. Clin. Oncol. 2000, 18 (16), 2938-2947.
65. Rothenberg, M. L.; Oza, A. M.; Bigelow, R. H.; Berlin, J. D.; Marshall, J. L.; Ramanathan, R. K.; Hart, L. L.; Gupta, S.; Garay, C. A.; Burger, B. G.; Le Bail, N.; Haller, D. G. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J. Clin. Oncol. 2003, 21 (11), 2059-2069.
66. Andre, T.; Boni, C.; Mounedji-Boudiaf, L.; Navarro, M.; Tabernero, J.; Hickish, T.; Topham, C.; Zaninelli, M.; Clingan, P.; Bridgewater, J.; Tabah-Fisch, I. de Gramont, A., Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon Cancer N. Engl. J. Med. 2004, 350 (23), 2343-2351.
67. Andre, T.; Boni, C.; Navarro, M.; Tabernero, J.; Hickish, T.; Topham, C.; Bonetti, A.; Clingan, P.; Bridgewater, J.; Rivera, F.; de Gramont, A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 2009, 27 (19), 3109-3116.
68. Kim, G. P.; Sargent, D. J.; Mahoney, M. R.; Rowland, K. M., Jr.; Philip, P. A.; Mitchell, E.; Mathews, A. P.; Fitch, T. R.; Goldberg, R. M.; Alberts, S. R.; Pitot, H. C. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorinin patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J. Clin. Oncol. 2009, 27 (17), 2848-2854.
69. Raymond, E.; Faivre, S.; Woynarowski, J. M.; Chaney, S. G., Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. 1998, 25 (2 Suppl 5), 4-12.
70. Chaney, S. G.; Campbell, S. L.; Bassett, E.; Wu, Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit. Rev. Oncol. Hematol. 2005, 53 (1), 3-11.
71. Marsh, S.; McLeod, H.; Dolan, E.; Shukla, S. J.; Rabik, C. A.; Gong, L.; Hernandez-Boussard, T.; Lou, X. J.; Klein, T. E.; Altman, R. B. Platinum pathway. Pharmacogenet. Genomics 2009, 19 (7), 563-564.
72. Graham, J.; Mushin, M.; Kirkpatrick, P. Oxaliplatin. Nat. Rev. Drug Discov. 2004, 3 (1), 11-2.
73. Jamieson, E. R.; Lippard, S. J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 1999, 99 (9), 2467-2498.
74. Kruh, G. D. Lustrous insights into cisplatin accumulation: copper transporters. Clin. Cancer Res. 2003, 9 (16 Pt 1), 5807-5809.
75. Yoh, K.; Ishii, G.; Yokose, T.; Minegishi, Y.; Tsuta, K.; Goto, K.; Nishiwaki, Y.; Kodama, T.; Suga, M.; Ochiai, A. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung. Cancer Clin. Cancer Res. 2004, 10 (5), 1691-1697.
76. Li, X. Q.; Li, J.; Shi, S. B.; Chen, P.; Yu, L. C.; Bao, Q. L. Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. Int. J. Biol. Markers 2009, 24 (4), 230-237.
77. Glaysher, S.; Yiannakis, D.; Gabriel, F. G.; Johnson, P.; Polak, M. E.; Knight, L. A.; Goldthorpe, Z.; Peregrin, K.; Gyi, M.; Modi, P.; Rahamim, J.; Smith, M. E.; Amer, K.; Addis, B.; Poole, M.; Narayanan, A.; Gulliford, T. J.; Andreotti, P. E.; Cree, I. A. Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC Cancer 2009, 9, 300.
78. Moyer, A. M.; Sun, Z.; Batzler, A. J.; Li, L.; Schaid, D. J.; Yang, P.; Weinshilboum, R. M. Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer Epidemiol. Biomarkers Prev. 2010, 19 (3), 811-821.
79. Fukushima-Uesaka, H.; Saito, Y.; Maekawa, K.; Kurose, K.; Sugiyama, E.; Katori, N.; Kaniwa, N.; Hasegawa, R.; Hamaguchi, T.; Eguchi-Nakajima, T.; Kato, K.; Yamada, Y.; Shimada, Y.; Yoshida, T.; Yamamoto, N.; Nokihara, H.; Kunitoh, H.; Ohe, Y.; Tamura, T.; Ura, T.; Saito, M.; Muro, K.; Doi, T.; Fuse, N.; Yoshino, T.; Ohtsu, A.; Saijo, N.; Matsumura, Y.; Okuda, H.; Sawada, J. Genetic polymorphisms of copper- and platinum drugefflux transporters ATP7A and ATP7B in Japanese cancer patients. Drug Metab. Pharmacokinet. 2009, 24 (6), 565-574.
80. Samimi, G.; Safaei, R.; Katano, K.; Holzer, A. K.; Rochdi, M.; Tomioka, M.; Goodman, M.; Howell, S. B. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin. Cancer Res. 2004, 10 (14), 4661-4669.
81. More, S. S.; Akil, O.; Ianculescu, A. G.; Geier, E. G.; Lustig, L. R.; Giacomini, K. M. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J. Neurosci. 2010, 30 (28), 9500-9509.
82. Sharma, S.; Gong, P.; Temple, B.; Bhattacharyya, D.; Dokholyan, N. V.; Chaney, S. G. Molecular dynamic simulations of cisplatinand oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics. J. Mol. Biol. 2007, 373 (5), 1123-1140.
83. Ramachandran, S.; Temple, B. R.; Chaney, S. G.; Dokholyan, N. V. Structural basis for the sequence-dependent effects of platinum-DNA adducts. Nucleic Acids Res. 2009, 37 (8), 2434-2448.
84. Freimuth, R. R.; Xiao, M.; Marsh, S.; Minton, M.; Addleman, N.; Van Booven, D. J.; McLeod, H. L.; Kwok, P. Y. Polymorphism discovery in 51 chemotherapy pathway genes. Hum. Mol. Genet. 2005, 14 (23), 3595-3603.
85. Pare, L.; Marcuello, E.; Altes, A.; del Rio, E.; Sedano, L.; Salazar, J.; Cortes, A.; Barnadas, A.; Baiget, M. Pharma cogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br. J. Cancer 2008, 99 (7), 1050-1055.
86. Liang, J.; Jiang, T.; Yao, R. Y.; Liu, Z. M.; Lv, H. Y.; Qi, W. W. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer. Br. Cancer chemotherapy and pharmacology 2010, 66 (3), 493-500.
87. Ruzzo, A.; Graziano, F.; Loupakis, F.; Rulli, E.; Canestrari, E.; Santini, D.; Catalano, V.; Ficarelli, R.; Maltese, P.; Bisonni, R.; Masi, G.; Schiavon, G.; Giordani, P.; Giustini, L.; Falcone, A.; Tonini, G.; Silva, R.; Mattioli, R.; Floriani, I.; Magnani, M. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J. Clin. Oncol. 2007, 25 (10), 1247-1254.
88. Hwang, I. G.; Ahn, M. J.; Park, B. B.; Ahn, Y. C.; Han, J.; Lee, S.; Kim, J.; Shim, Y. M.; Ahn, J. S.; Park, K. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patientstreated with platinum-based neoadjuvant concurrent chemor adiotherapy. Cancer 2008, 113 (6), 1379-1386.
89. Kim, S. H.; Kwon, H. C.; Oh, S. Y.; Lee, D. M.; Lee, S.; Lee, J. H.; Roh, M. S.; Kim, D. C.; Park, K. J.; Choi, H. J.; Kim, H. J. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am. J. Clin. Oncol. 2009, 32 (1), 38-43.
90. Vaisman, A.; Varchenko, M.; Umar, A.; Kunkel, T. A.; Risinger, J. I.; Barrett, J. C.; Hamilton, T. C.; Chaney, S. G. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res. 1998, 58 (16), 3579-3585.
91. Kane, M. F.; Loda, M.; Gaida, G. M.; Lipman, J.; Mishra, R.; Goldman, H.; Jessup, J. M.; Kolodner, R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumorcell lines. Cancer Res. 1997, 57 (5), 808-811.
92. Iacopetta, B.; Grieu, F.; Amanuel, B. Microsatellite instability in colorectal cancer. Asia Pac. J. Clin. Oncol. 2010, 6 (4), 260-269.
93. Albertella, M. R.; Green, C. M.; Lehmann, A. R.; O'Connor, M. J. A role for polymerase eta in the cellular tolerance to cisplatininduced damage. Cancer Res. 2005, 65 (21), 9799-9806.
94. Indovina, P.; Giordano, A. Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs. Cancer Biol. Ther. 2010, 9 (7), 523-525.
95. Hartwell, L. H.; Weinert, T. A. Checkpoints: controls that ensure the order of cell cycle events. Science 1989, 246 (4930), 629-634.
96. Pommier, Y.; Kohn, K.W. Cell cycle and checkpoints in oncology: new therapeutic targets. Med Sci (Paris). 2003, 19 (2), 173-186.
97. Hartwell, L. H.; Kastan, M. B. Cell cycle control and cancer. Science 1994, 266 (5192), 1821-1828.
98. Pommier, Y.; Sordet, O.; Rao, V. A.; Zhang, H.; Kohn, K. W. Targeting chk2 kinase: molecular interaction maps and therapeutic rationale. Curr. Pharm. Des. 2005, 11 (22), 2855-2872.
99. Reinhardt, H. C.; Yaffe, M. B. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr. Opin. CellBiol. 2009, 21 (2), 245-255.
100. Damia, G.; Broggini, M. Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents. Cell Cycle 2004, 3 (1), 46-50.
101. Hartwell, L.; Weinert, T.; Kadyk, L.; Garvik, B. Cell cycle checkpoints, genomic integrity, and cancer. Cold Spring Harb. Symp. Quant. Biol. 1994, 59, 259-263.
102. McKay, J. A.; Douglas, J. J.; Ross, V. G.; Curran, S.; Loane, J. F.; Ahmed, F. Y.; Cassidy, J.; McLeod, H. L.; Murray, G. I. Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J. Pathol. 2002, 196 (4), 386-393.
103. Kops, G. J.; Weaver, B. A.; Cleveland, D. W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 2005, 5 (10), 773-785.
104. Michel, L. S.; Liberal, V.; Chatterjee, A.; Kirchwegger, R.; Pasche, B.; Gerald, W.; Dobles, M.; Sorger, P. K.; Murty, V. V.; Benezra, R. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001, 409 (6818), 355-359.
105. Dai, W.; Wang, Q.; Liu, T.; Swamy, M.; Fang, Y.; Xie, S.; Mahmood, R.; Yang, Y. M.; Xu, M.; Rao, C. V. Slippage of mitotic arrest and enhanced tumor development in mice with BubR1 haploinsufficiency. Cancer Res. 2004, 64 (2), 440-445.
106. Baker, D. J.; Jeganathan, K. B.; Cameron, J. D.; Thompson, M.; Juneja, S.; Kopecka, A.; Kumar, R.; Jenkins, R. B.; de Groen, P. C.; Roche, P.; van Deursen, J. M. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat. Genet. 2004, 36 (7), 744-749.
107. Babu, J. R.; Jeganathan, K. B.; Baker, D. J.; Wu, X.; Kang-Decker, N. van Deursen, J. M., Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation. J. Cell Biol. 2003, 160 (3), 341-353.
108. Dalton, W. B.; Yang, V. W. Mitotic origins of chromosomal instability in colorectal cancer. Curr. Colorectal Cancer Rep. 2007,3 (2), 59-64.
109. Cahill, D. P.; Lengauer, C.; Yu, J.; Riggins, G. J.; Willson, J. K.; Markowitz, S. D.; Kinzler, K. W.; Vogelstein, B. Mutations of mitotic checkpoint genes in human cancers. Nature 1998, 392 (6673), 300-303.
110. Hanks, S.; Coleman, K.; Reid, S.; Plaja, A.; Firth, H.; Fitzpatrick, D.; Kidd, A.; Mehes, K.; Nash, R.; Robin, N.; Shannon, N.; Tolmie, J.; Swansbury, J.; Irrthum, A.; Douglas, J.; Rahman, N. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat. Genet. 2004, 36 (11), 1159-1161.
111. Lengauer, C.; Wang, Z. From spindle checkpoint to cancer. Nat. Genet. 2004, 36 (11), 1144-1145.
112. Wang, Z.; Cummins, J. M.; Shen, D.; Cahill, D. P.; Jallepalli, P. V.; Wang, T. L.; Parsons, D. W.; Traverso, G.; Awad, M.; Silliman, N.; Ptak, J.; Szabo, S.; Willson, J. K.; Markowitz, S. D.; Goldberg, M. L.; Karess, R.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E.; Lengauer, C. Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Res. 2004, 64 (9), 2998-3001.
113. Shichiri, M.; Yoshinaga, K.; Hisatomi, H.; Sugihara, K.; Hirata, Y. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res. 2002, 62 (1), 13-17.
114. Imai, Y.; Shiratori, Y.; Kato, N.; Inoue, T.; Omata, M. Mutational inactivation of mitotic checkpoint genes, hsMAD2 and hBUB1, is rare in sporadic digestive tract cancers. Jpn. J. Cancer Res. 1999, 90 (8), 837-840.
115. Rimkus, C.; Friederichs, J.; Rosenberg, R.; Holzmann, B.; Siewert, J. R.; Janssen, K. P. Expression of the mitotic checkpoint gene MAD2L2 has prognostic significance in colon cancer. Int. J. Cancer 2007, 120 (1), 207-211.
116. Li, G. Q.; Zhang, H. F. Mad2 and p27 expression profiles in colorectal cancer and its clinical significance. World J. Gastroenterol. 2004, 10 (21), 3218-3220.
117. Li, G. Q.; Li, H.; Zhang, H. F. Mad2 and p53 expression profiles in colorectal cancer and its clinical significance. World J.Gastroenterol. 2003, 9 (9), 1972-1975.
118. Menssen, A.; Epanchintsev, A.; Lodygin, D.; Rezaei, N.; Jung, P.; Verdoodt, B.; Diebold, J.; Hermeking, H. MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability. Cell Cycle 2007, 6 (3), 339-352.
119. Rodriguez-Antona, C. Pharmacogenomics of paclitaxel. Pharmacogenomics. 2010, 11 (5), 621-3.
120. Swanton, C.; Tomlinson, I.; Downward, J. Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle 2006, 5 (8), 818-823.
121. Furlan, D.; Casati, B.; Cerutti, R.; Facco, C.; Terracciano, L.; Capella, C.; Chiaravalli, A. M. Genetic progression in sporadic endometrial and gastrointestinal cancers with high microsatellite instability. J. Pathol. 2002, 197 (5), 603-609.
122. Bertoni, F.; Codegoni, A. M.; Furlan, D.; Tibiletti, M. G.; Capella, C.; Broggini, M. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer 1999, 26 (2), 176-180.
123. Bartek, J.; Lukas, J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003, 3 (5), 421-429.
124. Lewis, K. A.; Bakkum-Gamez, J.; Loewen, R.; French, A. J.; Thibodeau, S. N.; Cliby, W. A. Mutations in the ataxia telangiectasia and rad3-related-checkpoint kinase 1 DNA damage response axis in colon cancers. Genes Chromosomes Cancer 2007, 46 (12), 1061-1068.
125. Liu, W. D.; Zhong, B. Y.; Zhang, Y. D.; Choi, G. S. Mutation analysis of the checkpoint kinase 2 gene in colorectal cancer celllines. Chin. Med. J. (Engl). 2007, 120 (23), 2119-2123.
126. Bell, D. W.; Varley, J. M.; Szydlo, T. E.; Kang, D. H.; Wahrer, D. C.; Shannon, K. E.; Lubratovich, M.; Verselis, S. J.; Isselbacher, K. J.; Fraumeni, J. F.; Birch, J. M.; Li, F. P.; Garber, J. E.; Haber, D. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999, 286 (5449), 2528-2531.
127. Wu, X.; Webster, S. R.; Chen, J. Characterization of tumorassociated Chk2 mutations. J. Biol. Chem. 2001, 276 (4), 2971-2974.
128. Zoppoli, G.; Solier, S.; Reinhold, W. C.; Liu, H.; Connelly, J. W., Monks, A.; Shoemaker, R. H.; Abaan, O. D.; Davis, S. R.; Meltzer, P. S.; Doroshow, J. H.; Pommier, Y. CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. Oncogene 2012, 31 (4), 403-418.
129. Kilpivaara, O.; Laiho, P.; Aaltonen, L. A.; Nevanlinna, H., CHEK2 1100delC and colorectal cancer. J. Med. Genet. 2003, 40 (10), e110.
130. Meijers-Heijboer, H.; Wijnen, J.; Vasen, H.; Wasielewski, M.; Wagner, A.; Hollestelle, A.; Elstrodt, F.; van den Bos, R.; de Snoo, A.; Fat, G. T.; Brekelmans, C.; Jagmohan, S.; Franken, P.; Verkuijlen, P.; van den Ouweland, A.; Chapman, P.; Tops, C.; Moslein, G.; Burn, J.; Lynch, H.; Klijn, J.; Fodde, R.; Schutte, M. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am. J. Hum. Genet. 2003, 72 (5), 1308-1314.
131. de Jong, M. M.; Nolte, I. M.; Te Meerman, G. J.; van der Graaf, W. T.; Mulder, M. J.; van der Steege, G.; Bruinenberg, M.; Schaapveld, M.; Niessen, R. C.; Berends, M. J.; Sijmons, R. H.; Hofstra, R. M.; de Vries, E. G.; Kleibeuker, J. H. Colorectal cancer and the CHEK2 1100delC mutation. Genes Chromosomes Cancer 2005, 43 (4), 377-382.
132. van Puijenbroek, M.; van Asperen, C. J.; van Mil, A.; Devilee, P.; van Wezel, T.; Morreau, H. Homozygosity for a CHEK2*1100delCmutation identified in familial colorectal cancer does not lead to a severe clinical phenotype. J. Pathol. 2005, 206 (2), 198-204.
133. Schutte, M.; Seal, S.; Barfoot, R.; Meijers-Heijboer, H.; Wasielewski, M.; Evans, D. G.; Eccles, D.; Meijers, C.; Lohman, F.; Klijn, J.; van den Ouweland, A.; Futreal, P. A.; Nathanson, K.L.; Weber, B. L.; Easton, D. F.; Stratton, M. R.; Rahman, N. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am. J. Hum. Genet. 2003, 72 (4), 1023-1028.
134. Xiang, H. P.; Geng, X. P.; Ge, W. W.; Li, H. Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. Eur. J. Cancer 2011, 47 (17), 2546-2551.
135. Ioachim, E. Expression patterns of cyclins D1, E and cyclindependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features. Int. J. Clin. Pract. 2008, 62 (11), 1736-1743.
136. Zirbes, T. K.; Baldus, S. E.; Moenig, S. P.; Nolden, S.; Kunze, D.; Shafizadeh, S. T.; Schneider, P. M.; Thiele, J.; Hoelscher, A. H.; Dienes, H. P. Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int. J. Cancer 2000, 89 (1), 14-18.
137. Yasui, W.; Akama, Y.; Yokozaki, H.; Semba, S.; Kudo, Y.; Shimamoto, F.; Tahara, E. Expression of p21WAF1/CIP1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression. Pathol. Int. 1997, 47 (7), 470-477.
138. Tort, F.; Bartkova, J.; Sehested, M.; Orntoft, T.; Lukas, J.; Bartek, J. Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res. 2006, 66 (21), 10258-10263.
139. Rodrigues, N. R.; Rowan, A.; Smith, M. E.; Kerr, I. B.; Bodmer, W. F.; Gannon, J. V.; Lane, D. P. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 1990, 87 (19), 7555-7559.
140. Prudhomme, M. Novel checkpoint 1 inhibitors. Recent Pat Anticancer Drug Discov. 2006, 1 (1), 55-68.
141. Janetka, J. W.; Ashwell, S.; Zabludoff, S.; Lyne, P. Inhibitors of checkpoint kinases: from discovery to the clinic. Curr. Opin. Drug Discov. Devel. 2007, 10 (4), 473-486.
142. Collins, I.; Garrett, M. D. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr. Opin. Pharmacol. 2005, 5 (4), 366-373.
143. Wang, Q.; Fan, S.; Eastman, A.; Worland, P. J.; Sausville, E. A.; O'Connor, P. M. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 1996, 88 (14), 956-965.
144. Ashwell, S.; Zabludoff, S. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin. Cancer Res. 2008, 14 (13), 4032-4037.
145. Hernandez, L.; Cholody, W. M.; Hudson, E. A.; Resau, J. H.; Pauly, G.; Michejda, C. J. Mechanism of action of bisimidazoacridones, new drugs with potent, selective activity against colon cancer. Cancer Res. 1995, 55 (11), 2338-2345.
146. Cholody, W. M.; Kosakowska-Cholody, T.; Michejda, C. J. Bisimidazoacridones induce a potent cytostatic effect in colon tumor cells that sensitizes them to killing by UCN-01. Cancer Chemother. Pharmacol. 2001, 47 (3), 241-249.
147. Furuta, T.; Hayward, R. L.; Meng, L. H.; Takemura, H.; Aune, G. J.; Bonner, W. M.; Aladjem, M. I.; Kohn, K. W.; Pommier, Y. p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine. Oncogene 2006, 25 (20), 2839-2849.
148. Petersen, L.; Hasvold, G.; Lukas, J.; Bartek, J.; Syljuasen, R. G. p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors. Cell Prolif. 2010, 43 (4), 365-371.
149. Xiao, Z.; Xue, J.; Semizarov, D.; Sowin, T. J.; Rosenberg, S. H.; Zhang, H. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics. Int. J. Cancer 2005, 115 (4), 528-538.
150. Xiao, Z.; Xue, J.; Sowin, T. J.; Rosenberg, S. H.; Zhang, H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 2005, 24 (8), 1403-1411.
151. Castedo, M.; Perfettini, J. L.; Roumier, T.; Yakushijin, K.; Horne, D.; Medema, R.; Kroemer, G. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 2004, 23 (25), 4353-4361.
152. Jobson, A. G.; Lountos, G. T.; Lorenzi, P. L.; Llamas, J.; Connelly, J.; Cerna, D.; Tropea, J. E.; Onda, A.; Zoppoli, G.; Kondapaka, S.; Zhang, G.; Caplen, N. J.; Cardellina, J. H., 2nd; Yoo, S. S.; Monks, A.; Self, C.; Waugh, D. S.; Shoemaker, R. H.; Pommier, Y. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1- (guanidinohydrazone)-ethyl]-phenyl}-amide]. J. Pharmacol. Exp. Ther. 2009, 331 (3), 816-826.
153. Pires, I. M.; Ward, T. H.; Dive, C. Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors. Br. J. Pharmacol. 2010, 159 (6), 1326-1338.
154. Voland, C.; Bord, A.; Peleraux, A.; Penarier, G.; Carriere, D.; Galiegue, S.; Cvitkovic, E.; Jbilo, O.; Casellas, P. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol. Cancer Ther. 2006, 5 (9), 2149-2157.
155. Chen, C. R.; Wang, W.; Rogoff, H. A.; Li, X.; Mang, W.; Li, C. J. Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: checkpoint activation as a strategy against cancer. Cancer Res. 2005, 65 (14), 6017-6021.
156. Solier, S.; Sordet, O.; Kohn, K. W.; Pommier, Y. Death receptorinduced activation of the Chk2- and histone H2AX-associated DNA damage response pathways. Mol. Cell Biol. 2009, 29 (1), 68-82.
157. Wendt, J.; von Haefen, C.; Hemmati, P.; Belka, C.; Dorken, B.; Daniel, P. T. TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene 2005, 24 (25), 4052-4064.
158. Ray, S.; Shyam, S.; Fraizer, G. C.; Almasan, A. S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. Mol. Cancer Ther. 2007, 6 (4),1368-1378.
159. Aris, S. M.; Pommier, Y. Potentiation of the novel Topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor, AZD7762. Cancer Res. 2011.
160. Riesterer, O.; Matsumoto, F.; Wang, L.; Pickett, J.; Molkentine, D.; Giri, U.; Milas, L.; Raju, U. A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe. Invest. New Drugs 2011, 29 (3), 514-522.
161. Gupta, M.; Fan, S.; Zhan, Q.; Kohn, K. W.; O'Connor, P. M.; Pommier, Y. Inactivation of p53 increases the cytotoxicity ofcamptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin. Cancer Res. 1997, 3 (9), 1653-1660.
162. Chang, W. T.; Kang, J. J.; Lee, K. Y.; Wei, K.; Anderson, E.; Gotmare, S.; Ross, J. A.; Rosen, G. D. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J. Biol. Chem. 2001, 276 (3), 2221-2227.
163. Fidler, J. M.; Li, K.; Chung, C.; Wei, K.; Ross, J. A.; Gao, M.; Rosen, G. D. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol. Cancer Ther. 2003, 2 (9), 855-862.
164. Sayed, M.; Pelech, S.; Wong, C.; Marotta, A.; Salh, B. Protein kinase CK2 is involved in G2 arrest and apoptosis followingspindle damage in epithelial cells. Oncogene 2001, 20 (48), 6994-7005.
165. Kaestner, P.; Stolz, A.; Bastians, H. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinasesin human colon carcinoma cells. Mol. Cancer Ther. 2009, 8 (7), 2046-2056.
166. Redon, C. E.; Nakamura, A. J.; Zhang, Y. W.; Ji, J. J.; Bonner, W. M.; Kinders, R. J.; Parchment, R. E.; Doroshow, J. H.; Pommier, Y. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin. Cancer Res. 2010, 16 (18), 4532-4542.
167. Rouleau, M.; Patel, A.; Hendzel, M. J.; Kaufmann, S. H.; Poirier, G. G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 2010, 10 (4), 293-301.
168. Kim, M. Y.; Zhang, T.; Kraus, W. L. Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. Genes Dev. 2005, 19 (17), 1951-1967.
169. Schreiber, V.; Dantzer, F.; Ame, J. C.; de Murcia, G. Poly(ADPribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7 (7), 517-528.
170. Ju, B. G.; Lunyak, V. V.; Perissi, V.; Garcia-Bassets, I.; Rose, D. W.; Glass, C. K.; Rosenfeld, M. G. A topoisomerase IIbetamediateddsDNA break required for regulated transcription. Science 2006, 312 (5781), 1798-1802.
171. Lis, J. T.; Kraus, W. L. Promoter cleavage: a topoIIbeta and PARP- 1 collaboration. Cell 2006, 125 (7), 1225-7.
172. Caldecott, K. W. XRCC1 and DNA strand break repair. DNA Repair (Amst). 2003, 2 (9), 955-969.
173. Masson, M.; Niedergang, C.; Schreiber, V.; Muller, S.; Menissierde Murcia, J.; de Murcia, G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol. Cell Biol. 1998, 18 (6), 3563-3571.
174. El-Khamisy, S. F.; Masutani, M.; Suzuki, H.; Caldecott, K. W. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 2003, 31 (19), 5526-5533.
175. Audebert, M.; Salles, B.; Calsou, P. Involvement of poly(ADPribose) polymerase-1 and XRCC1/DNA ligase III in an alternativeroute for DNA double-strand breaks rejoining. J. Biol. Chem. 2004, 279 (53), 55117-55126.
176. Iliakis, G. Backup pathways of NHEJ in cells of higher eukaryotes: cell cycle dependence. Radiother. Oncol. 2009, 92 (3), 310-315.
177. Rouleau, M.; Patel, A.; Hendzel, M. J.; Kaufmann, S. H.; Poirier, G. G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 2010, 10 (4), 293-301.
178. Drew, Y.; Plummer, R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist. Updat. 2009, 12 (6), 153-156.
179. Annunziata, C. M.; O'Shaughnessy, J. Poly (adp-ribose) polymerase as a novel therapeutic target in cancer. Clin. Cancer Res. 2010, 16 (18), 4517-4526.
180. Bryant, H. E.; Schultz, N.; Thomas, H. D.; Parker, K. M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N. J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434 (7035), 913-917.
181. Farmer, H.; McCabe, N.; Lord, C. J.; Tutt, A. N.; Johnson, D. A.; Richardson, T. B.; Santarosa, M.; Dillon, K. J.; Hickson, I.; Knights, C.; Martin, N. M.; Jackson, S. P.; Smith, G. C.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434 (7035), 917-921.
182. Nosho, K.; Yamamoto, H.; Mikami, M.; Taniguchi, H.; Takahashi, T.; Adachi, Y.; Imamura, A.; Imai, K.; Shinomura, Y. Over expression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur. J. Cancer 2006, 42 (14), 2374-2381.
183. Cristovao, L.; Lechner, M. C.; Fidalgo, P.; Leitao, C. N.; Mira, F. C.; Rueff, J. Absence of stimulation of poly(ADP-ribose) polymerase activity in patients predisposed to colon cancer. Br. J. Cancer 1998, 77 (10), 1628-1632.
184. Stern, M. C.; Conti, D. V.; Siegmund, K. D.; Corral, R.; Yuan, J. M.; Koh, W. P.; Yu, M. C. DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study. Cancer Epidemiol. Biomarkers Prev. 2007, 16 (11), 2363-2372.
185. Brevik, A.; Joshi, A. D.; Corral, R.; Onland-Moret, N. C.; Siegmund, K. D.; Le Marchand, L.; Baron, J. A.; Martinez, M. E.; Haile, R. W.; Ahnen, D.; Sandler, R. S.; Lance, P.; Stern, M. C. Polymorphisms in base excision repair genes as colorectal cancer risk factors and modifiers of the effect of diets high in red meat. Cancer Epidemiol. Biomarkers Prev. 2010, 19 (12), 3167-3173.
186. Calabrese, C. R.; Almassy, R.; Barton, S.; Batey, M. A.; Calvert, A. H.; Canan-Koch, S.; Durkacz, B. W.; Hostomsky, Z.; Kumpf, R. A.; Kyle, S.; Li, J.; Maegley, K.; Newell, D. R.; Notarianni, E.; Stratford, I. J.; Skalitzky, D.; Thomas, H. D.; Wang, L. Z.; Webber, S. E.; Williams, K. J.; Curtin, N. J. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. 2004, 96 (1), 56-67.
187. Donawho, C. K.; Luo, Y.; Penning, T. D.; Bauch, J. L.; Bouska, J. J.; Bontcheva-Diaz, V. D.; Cox, B. F.; DeWeese, T. L.; Dillehay, L. E.; Ferguson, D. C.; Ghoreishi-Haack, N. S.; Grimm, D. R.; Guan, R.; Han, E. K.; Holley-Shanks, R. R.; Hristov, B.; Idler, K. B.; Jarvis, K.; Johnson, E. F.; Kleinberg, L. R.; Klinghofer, V.; Lasko, L. M.; Liu, X.; Marsh, K. C.; McGonigal, T. P.; Meulbroek, J. A.; Olson, A. M.; Palma, J. P.; Rodriguez, L. E.; Shi, Y.; Stavropoulos, J. A.; Tsurutani, A. C.; Zhu, G. D.; Rosenberg, S. H.; Giranda, V. L.; Frost, D. J. ABT-888, an orally active poly(ADPribose) polymerase inhibitor that potentiates DNA-damaging agentsin preclinical tumor models. Clin. Cancer Res. 2007, 13 (9), 2728-2737.
188. Liu, X.; Shi, Y.; Guan, R.; Donawho, C.; Luo, Y.; Palma, J.; Zhu, G. D.; Johnson, E. F.; Rodriguez, L. E.; Ghoreishi-Haack, N.; Jarvis, K.; Hradil, V. P.; Colon-Lopez, M.; Cox, B. F.; Klinghofer, V.; Penning, T.; Rosenberg, S. H.; Frost, D.; Giranda, V. L. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of singlestranded DNA damages to double-stranded DNA breaks. Mol. Cancer Res. 2008, 6 (10), 1621-1629.
189. Tentori, L.; Leonetti, C.; Scarsella, M.; Muzi, A.; Mazzon, E.; Vergati, M.; Forini, O.; Lapidus, R.; Xu, W.; Dorio, A. S.; Zhang, J.; Cuzzocrea, S.; Graziani, G. Inhibition of poly(ADP-ribose)polymerase prevents irinotecan-induced intestinal damage and enhances ir inotecan/temozolomide efficacy against colon carcinoma. FASEB J. 2006, 20 (10), 1709-1711.
190. Amador, M. L.; Hidalgo, M. Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer. Clin. Colorectal Cancer 2004, 4 (1), 51-62.
191. Hemming, A. W.; Davis, N. L.; Kluftinger, A.; Robinson, B.; Quenville, N. F.; Liseman, B.; LeRiche, J. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J. Surg. Oncol. 1992, 51 (3), 147-152.
192. Mayer, A.; Takimoto, M.; Fritz, E.; Schellander, G.; Kofler, K.; Ludwig, H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993, 71 (8), 2454-2460.
193. Bronte, G.; Terrasi, M.; Rizzo, S.; Sivestris, N.; Ficorella, C.; Cajozzo, M.; Di Gaudio, F.; Gulotta, G.; Siragusa, S.; Gebbia, N.; Russo, A. EGFR genomic alterations in cancer: prognostic and predictive values. Front. Biosci. (Elite Ed). 2011, 3, 879-887.
194. Buisine, M. P.; Wacrenier, A.; Mariette, C.; Leteurtre, E.; Escande, F.; Aissi, S.; Ketele, A.; Leclercq, A.; Porchet, N.; Lesuffleur, T. Frequent mutations of the CA simple sequence repeat in intron 1 of EGFR in mismatch repair-deficient colorectal cancers. World J.Gastroenterol. 2008, 14 (7), 1053-1059.
195. Bijnsdorp, I. V.; Kruyt, F. A.; Fukushima, M.; Smid, K.; Gokoel, S.; Peters, G. J. Molecular mechanism underlying the synergisticinteraction between tri fluoro thymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines. Cancer Sci. 2010, 101 (2), 440-447.
196. Hiro, J.; Inoue, Y.; Toiyama, Y.; Miki, C.; Kusunoki, M. Mechanism of resistance to chemoradiation in p53 mutant human colon cancer. Int. J. Oncol. 2008, 32 (6), 1305-1310.
197. Vigneron, A.; Gamelin, E.; Coqueret, O. The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. Cancer Res. 2008, 68 (3), 815-825.
198. Xu, J. M.; Azzariti, A.; Severino, M.; Lu, B.; Colucci, G.; Paradiso, A. Characterization of sequence-dependent synergy between ZD1839 (Iressa) and oxaliplatin. Biochem. Pharmacol. 2003, 66 (4), 551-563.
199. Haggblad Sahlberg, S.; Spiegelberg, D.; Lennartsson, J.; Nygren, P.; Glimelius, B.; Stenerlow, B. The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR. Int. J. Oncol. 2012, 40(1), 176-184.